Codexis to Participate in Enzymatic Synthesis Presentations
Codexis, Inc. (NASDAQ: CDXS), a frontrunner in enzyme engineering, has announced its participation in the upcoming RNA Leaders annual meeting. This event will highlight innovative strategies for manufacturing short inhibitory ribonucleic acid (siRNA) duplexes.
Keynote Presentation Details
During a keynote panel, Stefan Lutz, PhD, the Senior Vice President of Research at Codexis, will join other prominent figures in the RNA industry to discuss advancements in RNA manufacturing processes and strategies aimed at improving production capabilities.
Focus on Ligation for siRNA Manufacturing
Codexis will also showcase ligation techniques that facilitate the efficient synthesis of siRNA duplexes. This presentation will emphasize cost reductions achieved through short fragment synthesis, highlighting the company's state-of-the-art enzyme technology and optimization services designed to enhance performance and scalability in manufacturing.
About RNAi Therapeutics Manufacturing
Ribonucleic acid (RNA) has become a vital therapeutic option, especially with the increasing prominence of mRNA vaccines and siRNA candidates. However, traditional manufacturing methods encounter challenges related to quality control and scalability. With over 450 RNAi therapies currently in development, Codexis is committed to addressing the growing demand by refining its production techniques.
Introducing the ECO Synthesis™ Manufacturing Platform
To enhance the scalability and cost-effectiveness of RNAi therapeutics, Codexis has developed the Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ platform. Recent presentations have demonstrated successful enzymatic synthesis processes that achieve higher purity and efficiency compared to conventional methods.
About Codexis
Codexis specializes in enzyme engineering, leveraging its proprietary technology to create high-performance enzymes that tackle challenges in pharmaceuticals and nucleic acid synthesis. The company's dedication to innovation fosters greater efficiency, reduced waste, and improved manufacturing practices.
Frequently Asked Questions
What is the focus of Codexis' presentations?
Codexis will concentrate on enzyme-driven methods to enhance siRNA manufacturing, showcasing their innovations at the RNA Leaders meeting.
Who will represent Codexis at the conference?
Stefan Lutz, PhD, and Mathew Miller, PhD, will present advancements in RNA manufacturing and the ECO Synthesis™ platform, respectively.
What challenges does RNA manufacturing face today?
Current RNA manufacturing methods grapple with issues of quality control, scalability, and economic efficiency, especially as the demand for RNA therapeutics continues to grow.
What is the ECO Synthesis™ platform?
The ECO Synthesis™ platform is Codexis' proprietary technology aimed at enabling scalable and cost-effective production of RNA therapeutics through enzymatic processes.
How does Codexis contribute to the field of pharmaceuticals?
Codexis enhances pharmaceutical manufacturing by providing innovative enzyme solutions that improve yields, minimize waste, and advance nucleic acid synthesis.
